NO314401B1 - Nye, 4-substituerte piperidiner, farmasöytisk preparat inneholdende disse og anvendelse av dem for fremstilling av et medikament - Google Patents
Nye, 4-substituerte piperidiner, farmasöytisk preparat inneholdende disse og anvendelse av dem for fremstilling av et medikament Download PDFInfo
- Publication number
- NO314401B1 NO314401B1 NO19995643A NO995643A NO314401B1 NO 314401 B1 NO314401 B1 NO 314401B1 NO 19995643 A NO19995643 A NO 19995643A NO 995643 A NO995643 A NO 995643A NO 314401 B1 NO314401 B1 NO 314401B1
- Authority
- NO
- Norway
- Prior art keywords
- methylpiperidine
- phenyl
- fluorophenoxy
- general formula
- fluorophenyl
- Prior art date
Links
- -1 4-substituted piperidines Chemical class 0.000 title claims description 68
- 239000003814 drug Substances 0.000 title claims 3
- 229940079593 drug Drugs 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
- 150000005840 aryl radicals Chemical class 0.000 claims description 10
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000005978 1-naphthyloxy group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000005001 aminoaryl group Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- IFLKJNRBPLFYGN-UHFFFAOYSA-N 2-[2-(piperidin-4-ylmethyl)phenoxy]benzonitrile Chemical compound N#CC1=CC=CC=C1OC1=CC=CC=C1CC1CCNCC1 IFLKJNRBPLFYGN-UHFFFAOYSA-N 0.000 claims 1
- ODSBSRZBVUHGOE-UHFFFAOYSA-N 2-chloro-4-[2-(piperidin-4-ylmethyl)phenoxy]benzonitrile Chemical compound C1=C(C#N)C(Cl)=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 ODSBSRZBVUHGOE-UHFFFAOYSA-N 0.000 claims 1
- CJCWGYZBCZZSCB-UHFFFAOYSA-N 3-[2-(piperidin-4-ylmethyl)phenoxy]benzonitrile Chemical compound N#CC1=CC=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 CJCWGYZBCZZSCB-UHFFFAOYSA-N 0.000 claims 1
- DBAGHOSHBXJBOJ-UHFFFAOYSA-N 3-fluoro-5-[2-(piperidin-4-ylmethyl)phenoxy]benzonitrile Chemical compound N#CC1=CC(F)=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 DBAGHOSHBXJBOJ-UHFFFAOYSA-N 0.000 claims 1
- YMWHQRWYHLZCPE-UHFFFAOYSA-N 4-[(2-naphthalen-1-yloxyphenyl)methyl]piperidine Chemical compound C=1C=CC=C(OC=2C3=CC=CC=C3C=CC=2)C=1CC1CCNCC1 YMWHQRWYHLZCPE-UHFFFAOYSA-N 0.000 claims 1
- NUPQKNDDLUZCHJ-UHFFFAOYSA-N 4-[[2-(2-fluorophenoxy)phenyl]methyl]piperidine Chemical compound FC1=CC=CC=C1OC1=CC=CC=C1CC1CCNCC1 NUPQKNDDLUZCHJ-UHFFFAOYSA-N 0.000 claims 1
- AWAGTLRDEWUEHS-UHFFFAOYSA-N 4-[[2-(2-phenylphenoxy)phenyl]methyl]piperidine Chemical compound C=1C=CC=C(OC=2C(=CC=CC=2)C=2C=CC=CC=2)C=1CC1CCNCC1 AWAGTLRDEWUEHS-UHFFFAOYSA-N 0.000 claims 1
- MGKGKZLGLCZYBS-UHFFFAOYSA-N 4-[[2-(3,4-dichlorophenoxy)phenyl]methyl]piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1OC1=CC=CC=C1CC1CCNCC1 MGKGKZLGLCZYBS-UHFFFAOYSA-N 0.000 claims 1
- CMTSSHXAGKUMGZ-UHFFFAOYSA-N 4-[[2-(3,5-difluorophenoxy)phenyl]methyl]piperidine Chemical compound FC1=CC(F)=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 CMTSSHXAGKUMGZ-UHFFFAOYSA-N 0.000 claims 1
- AHDVTXZWTIFXTL-UHFFFAOYSA-N 4-[[2-(3-bromophenoxy)phenyl]methyl]piperidine Chemical compound BrC1=CC=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 AHDVTXZWTIFXTL-UHFFFAOYSA-N 0.000 claims 1
- GLVUWLAKBXJANP-UHFFFAOYSA-N 4-[[2-(3-chloro-2-methylphenoxy)phenyl]methyl]piperidine Chemical compound CC1=C(Cl)C=CC=C1OC1=CC=CC=C1CC1CCNCC1 GLVUWLAKBXJANP-UHFFFAOYSA-N 0.000 claims 1
- NRORBVMNXXWGJU-UHFFFAOYSA-N 4-[[2-(3-chlorophenoxy)phenyl]methyl]piperidine Chemical compound ClC1=CC=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 NRORBVMNXXWGJU-UHFFFAOYSA-N 0.000 claims 1
- MNFSQJAAMJEOEH-UHFFFAOYSA-N 4-[[2-(3-fluoro-2-methylphenoxy)phenyl]methyl]piperidine Chemical compound CC1=C(F)C=CC=C1OC1=CC=CC=C1CC1CCNCC1 MNFSQJAAMJEOEH-UHFFFAOYSA-N 0.000 claims 1
- TZBDPVDFTUIJSM-UHFFFAOYSA-N 4-[[2-(3-fluoro-5-methoxyphenoxy)phenyl]methyl]piperidine Chemical compound COC1=CC(F)=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 TZBDPVDFTUIJSM-UHFFFAOYSA-N 0.000 claims 1
- IHEZILCVDSHHPQ-UHFFFAOYSA-N 4-[[2-(3-iodophenoxy)phenyl]methyl]piperidine Chemical compound IC1=CC=CC(OC=2C(=CC=CC=2)CC2CCNCC2)=C1 IHEZILCVDSHHPQ-UHFFFAOYSA-N 0.000 claims 1
- XNSGTHYTWUGMFJ-UHFFFAOYSA-N 4-[[2-(4-iodophenoxy)phenyl]methyl]piperidine Chemical compound C1=CC(I)=CC=C1OC1=CC=CC=C1CC1CCNCC1 XNSGTHYTWUGMFJ-UHFFFAOYSA-N 0.000 claims 1
- OETMRKDCAPITCE-UHFFFAOYSA-N 4-[[2-(4-phenylphenoxy)phenyl]methyl]piperidine Chemical compound C=1C=CC=C(OC=2C=CC(=CC=2)C=2C=CC=CC=2)C=1CC1CCNCC1 OETMRKDCAPITCE-UHFFFAOYSA-N 0.000 claims 1
- SYYWVRKVUAEWLM-UHFFFAOYSA-N 4-[[2-(5-chloro-2-methylphenoxy)phenyl]methyl]piperidine Chemical compound CC1=CC=C(Cl)C=C1OC1=CC=CC=C1CC1CCNCC1 SYYWVRKVUAEWLM-UHFFFAOYSA-N 0.000 claims 1
- FXGGCUSKJSBTGD-UHFFFAOYSA-N 4-[[3-fluoro-2-(2-fluorophenoxy)phenyl]methyl]piperidine Chemical compound FC1=CC=CC=C1OC1=C(F)C=CC=C1CC1CCNCC1 FXGGCUSKJSBTGD-UHFFFAOYSA-N 0.000 claims 1
- MLJQQQUDDZEUNW-UHFFFAOYSA-N 4-[[3-fluoro-2-(3-fluorophenoxy)phenyl]methyl]piperidine Chemical compound FC1=CC=CC(OC=2C(=CC=CC=2F)CC2CCNCC2)=C1 MLJQQQUDDZEUNW-UHFFFAOYSA-N 0.000 claims 1
- PVAVCXMPBXQVLF-UHFFFAOYSA-N 4-[[3-fluoro-2-(4-fluorophenoxy)phenyl]methyl]piperidine Chemical compound C1=CC(F)=CC=C1OC1=C(F)C=CC=C1CC1CCNCC1 PVAVCXMPBXQVLF-UHFFFAOYSA-N 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 125000003386 piperidinyl group Chemical group 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- FPMPNYWHRPRYLO-UHFFFAOYSA-N 4-[[2-(4-fluorophenoxy)phenyl]methyl]piperidine Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1CC1CCNCC1 FPMPNYWHRPRYLO-UHFFFAOYSA-N 0.000 description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 239000004300 potassium benzoate Substances 0.000 description 5
- 229940103091 potassium benzoate Drugs 0.000 description 5
- 235000010235 potassium benzoate Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- DUZLYYVHAOTWSF-UHFFFAOYSA-N phenyl(piperidin-4-yl)methanol Chemical compound C=1C=CC=CC=1C(O)C1CCNCC1 DUZLYYVHAOTWSF-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 3
- QUGUFLJIAFISSW-UHFFFAOYSA-N 1,4-difluorobenzene Chemical compound FC1=CC=C(F)C=C1 QUGUFLJIAFISSW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000000697 serotonin reuptake Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 2
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 2
- CIPPXCKZRNTZQA-UHFFFAOYSA-N 4-[[2-(4-bromophenoxy)phenyl]methyl]piperidine Chemical compound C1=CC(Br)=CC=C1OC1=CC=CC=C1CC1CCNCC1 CIPPXCKZRNTZQA-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001926 alkyl arylether group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000000966 norepinephrine reuptake Effects 0.000 description 2
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical compound NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- DDRCHUGHUHZNKZ-UHFFFAOYSA-N phenyl(piperidin-4-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCNCC1 DDRCHUGHUHZNKZ-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- UQADQTBQNVARAP-UHFFFAOYSA-N tert-butyl 4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1 UQADQTBQNVARAP-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- XNKHJZCJAGGHNK-WLHGVMLRSA-N (E)-but-2-enedioic acid 1-methylpiperidine Chemical compound CN1CCCCC1.OC(=O)\C=C\C(O)=O XNKHJZCJAGGHNK-WLHGVMLRSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- XWCURTFWZXHKSB-UHFFFAOYSA-N 3-[(2-phenoxyphenyl)methyl]piperidine Chemical compound C=1C=CC=C(OC=2C=CC=CC=2)C=1CC1CCCNC1 XWCURTFWZXHKSB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WDRJNKMAZMEYOF-UHFFFAOYSA-N 4-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(OC(F)(F)F)C=C1 WDRJNKMAZMEYOF-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical class FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- QDUXDCXILAPLAG-UHFFFAOYSA-N hydron;1-methylpiperidine;chloride Chemical compound Cl.CN1CCCCC1 QDUXDCXILAPLAG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229950004211 nisoxetine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- FSDNTQSJGHSJBG-UHFFFAOYSA-N piperidine-4-carbonitrile Chemical compound N#CC1CCNCC1 FSDNTQSJGHSJBG-UHFFFAOYSA-N 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- PNCDXUYGMZPOLQ-UHFFFAOYSA-N tert-butyl 4-(3-fluorobenzoyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(=O)C1=CC=CC(F)=C1 PNCDXUYGMZPOLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009802420A ES2157148B1 (es) | 1998-11-18 | 1998-11-18 | Nuevas piperidinas 4-sustituidas. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995643D0 NO995643D0 (no) | 1999-11-17 |
| NO995643L NO995643L (no) | 2000-05-19 |
| NO314401B1 true NO314401B1 (no) | 2003-03-17 |
Family
ID=8305832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995643A NO314401B1 (no) | 1998-11-18 | 1999-11-17 | Nye, 4-substituerte piperidiner, farmasöytisk preparat inneholdende disse og anvendelse av dem for fremstilling av et medikament |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1002794B1 (tr) |
| JP (1) | JP4667552B2 (tr) |
| KR (1) | KR100646675B1 (tr) |
| AR (1) | AR028805A1 (tr) |
| AT (1) | ATE422199T1 (tr) |
| AU (1) | AU757177B2 (tr) |
| BR (1) | BR9905634B1 (tr) |
| CA (1) | CA2288533C (tr) |
| CY (1) | CY1108955T1 (tr) |
| CZ (1) | CZ296053B6 (tr) |
| DE (1) | DE69940378D1 (tr) |
| DK (1) | DK1002794T3 (tr) |
| ES (2) | ES2157148B1 (tr) |
| HR (1) | HRP990354B1 (tr) |
| HU (1) | HU227558B1 (tr) |
| IL (1) | IL132862A0 (tr) |
| NO (1) | NO314401B1 (tr) |
| PL (1) | PL196329B1 (tr) |
| PT (1) | PT1002794E (tr) |
| RU (1) | RU2232753C2 (tr) |
| TR (1) | TR199902839A2 (tr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513510A1 (en) * | 2002-05-30 | 2005-03-16 | Head Explorer A/S | The use of milnacipran for the treatment of tension-type headache |
| UA77536C2 (en) * | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
| US7521462B2 (en) | 2004-02-27 | 2009-04-21 | Eli Lilly And Company | 4-Amino-piperidine derivatives as monoamine uptake inhibitors |
| BRPI0512236A (pt) | 2004-06-18 | 2008-02-19 | Wyeth Corp | processos para a preparação de 6-alquil-5-arilsulfonil-diidrofenantridinas |
| EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| US20100120858A1 (en) * | 2006-08-23 | 2010-05-13 | Pfizer Inc. | Piperidine Derivatives |
| CA2742105C (en) * | 2008-11-14 | 2016-09-13 | Theravance, Inc. | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| US20100267743A1 (en) * | 2009-04-15 | 2010-10-21 | Stangeland Eric L | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| EP2390248A1 (en) | 2010-05-24 | 2011-11-30 | Faes Farma, S.A. | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
| MX2012013581A (es) | 2010-05-24 | 2013-02-15 | Faes Farma Sa | Derivados de flufenoxina para el tratamiento y la prevencion de patologias amiloides. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
| JPH0615529B2 (ja) * | 1985-04-01 | 1994-03-02 | エーザイ株式会社 | 新規ピペリジン誘導体 |
| JPH0840999A (ja) * | 1994-08-04 | 1996-02-13 | Yamanouchi Pharmaceut Co Ltd | フルオロインダン誘導体 |
| CO5150201A1 (es) * | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | Derivados de piperidina |
-
1998
- 1998-11-18 ES ES009802420A patent/ES2157148B1/es not_active Expired - Fee Related
-
1999
- 1999-11-04 CA CA002288533A patent/CA2288533C/en not_active Expired - Fee Related
- 1999-11-08 HU HU9904086A patent/HU227558B1/hu not_active IP Right Cessation
- 1999-11-09 AR ARP990105657A patent/AR028805A1/es active IP Right Grant
- 1999-11-10 EP EP99500208A patent/EP1002794B1/en not_active Expired - Lifetime
- 1999-11-10 ES ES99500208T patent/ES2323742T3/es not_active Expired - Lifetime
- 1999-11-10 CZ CZ19993995A patent/CZ296053B6/cs not_active IP Right Cessation
- 1999-11-10 AT AT99500208T patent/ATE422199T1/de active
- 1999-11-10 DE DE69940378T patent/DE69940378D1/de not_active Expired - Lifetime
- 1999-11-10 PT PT99500208T patent/PT1002794E/pt unknown
- 1999-11-10 IL IL13286299A patent/IL132862A0/xx not_active IP Right Cessation
- 1999-11-10 DK DK99500208T patent/DK1002794T3/da active
- 1999-11-11 AU AU59366/99A patent/AU757177B2/en not_active Ceased
- 1999-11-16 HR HR990354A patent/HRP990354B1/xx not_active IP Right Cessation
- 1999-11-17 KR KR1019990051053A patent/KR100646675B1/ko not_active IP Right Cessation
- 1999-11-17 RU RU99124412/04A patent/RU2232753C2/ru not_active IP Right Cessation
- 1999-11-17 PL PL336607A patent/PL196329B1/pl not_active IP Right Cessation
- 1999-11-17 NO NO19995643A patent/NO314401B1/no not_active IP Right Cessation
- 1999-11-17 BR BRPI9905634-8A patent/BR9905634B1/pt not_active IP Right Cessation
- 1999-11-17 TR TR1999/02839A patent/TR199902839A2/tr unknown
- 1999-11-18 JP JP32888599A patent/JP4667552B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-02 CY CY20091100388T patent/CY1108955T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6610711B2 (en) | 4-phenylpiperidines for the treatment of pruritic dermatoses | |
| US5116846A (en) | N-aralkyl piperidine derivatives as psychotropic drugs | |
| JP4754494B2 (ja) | Ｎ−［フェニル（アルキルピペリジン−２−イル）メチル］ベンズアミド誘導体、この調製方法およびこの治療法における使用 | |
| DE69221919T2 (de) | Piperidin-Derivate | |
| US5021428A (en) | Novel chemical compounds for the prophylactic treatment of migraine | |
| JPH0655720B2 (ja) | 新規化合物類 | |
| US20100004283A1 (en) | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
| US6518284B2 (en) | 4-substituted piperidines | |
| NO314401B1 (no) | Nye, 4-substituerte piperidiner, farmasöytisk preparat inneholdende disse og anvendelse av dem for fremstilling av et medikament | |
| JPS6135175B2 (tr) | ||
| JP5027208B2 (ja) | セロトニントランスポータ阻害剤およびニューロキニン−１受容体アンタゴニストとして有用なピペリジン誘導体 | |
| US5846980A (en) | N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants | |
| JP2006508110A (ja) | 新規な２，３−ジヒドロ−４（１ｈ）−ピリジノン誘導体、それらの製造方法およびそれらを含む医薬組成物 | |
| MXPA99010525A (en) | 4-[(aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | |
| DK157853B (da) | Analogifremgangsmaade til fremstilling af 4-benzyloxypiperidinderivater | |
| JPS63201185A (ja) | ピロカルピン誘導体 | |
| JPH08208595A (ja) | スルホンアミド化合物、その製造法および剤 | |
| MXPA00011393A (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | |
| JP2008506645A (ja) | ５−ｈｔ／ｎａ取り込み阻害剤としての置換されたアミノ化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |